[Skip to Content]
[Skip to Content Landing]
Views 241
Citations 0
Comment & Response
March 2016

Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ

Author Affiliations
  • 1Center for Applied Proteomics and Molecular Medicine, Institute for Advanced Biomedical Research College of Science, George Mason University, Manassas, Virginia
  • 2Novant Health Breast Center, Novant Health Haymarket Medical Center, Haymarket, Virginia
JAMA Oncol. 2016;2(3):395. doi:10.1001/jamaoncol.2015.4846

To the Editor Esserman and Yau1 recommend that whereas high-risk breast ductal carcinoma in situ (DCIS) lesions should still be aggressively treated, the lower-risk lesions are candidates for observation alone, or risk reduction therapies, instead of definitive surgery. Indeed, the 10-year survival benefit after surgical excision was significant for intermediate and high-grade, but not low-grade, DCIS.2

First Page Preview View Large
First page PDF preview
First page PDF preview
×